Gene-expression profiling of Waldenström macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma

Author:

Chng Wee J.1,Schop Roelandt F.1,Price-Troska Tammy1,Ghobrial Irene1,Kay Neil1,Jelinek Diane F.1,Gertz Morie A.1,Dispenzieri Angela1,Lacy Martha1,Kyle Robert A.1,Greipp Philip R.1,Tschumper Renee C.1,Fonseca Rafael1,Bergsagel Peter Leif1

Affiliation:

1. From the Department of Hematology-Oncology, Mayo Clinic Scottsdale, AZ; Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN; Dana Faber Cancer Institute, Boston, MA; Division of Internal Medicine, Mayo Clinic College of Medicine, Mayo Graduate School, Rochester, MN; Department of Immunology and Division of Hematology, Mayo Clinic College of Medicine, Mayo Graduate School, Rochester, MN.

Abstract

AbstractWaldenström macroglobulinemia (WM) is a B-cell malignancy characterized by the ability of the B-cell clone to differentiate into plasma cells. Although the clinical syndrome and the pathologic characteristics are well defined, little is known about its biology and controversy still exists regarding its cell of origin. In this gene-expression study, we compared the transcription profiles of WM with those of other malignant B cells including (chronic lymphocytic leukemia [CLL] and multiple myeloma [MM]) as well as normal cells (peripheral-blood B cells and bone marrow plasma cells). We found that WM has a homogenous gene expression regardless of 6q deletion status and clusters with CLL and normal B cells on unsupervised clustering with very similar expression profiles. Only a small gene set has expression profiles unique to WM compared to CLL and MM. The most significantly up-regulated gene is IL6 and the most significantly associated pathway for this set of genes is MAPK signaling. Thus, IL6 and its downstream signaling may be of biologic importance in WM. Further elucidation of the role of IL-6 in WM is warranted as this may offer a potential therapeutic avenue.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Cited by 146 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. The Management of Relapsed or Refractory Waldenström’s Macroglobulinemia;Hematology/Oncology Clinics of North America;2023-08

2. BTK Inhibitors and Other Targeted Therapies in Waldenström Macroglobulinemia;Hemato;2023-04-13

3. Clinical Experience with Pro‐Apoptotic Agents;Precision Cancer Therapies, Volume 1 ‐ Targeting Oncogenic Drivers and Signaling Pathways in Lymphoid Malignancies;2023-03-15

4. Treatment of relapsed and refractory Waldenstrom Macroglobulinemia;Leukemia & Lymphoma;2022-10-25

5. Clinical experiences with venetoclax and other pro-apoptotic agents in lymphoid malignancies: lessons from monotherapy and chemotherapy combination;Journal of Hematology & Oncology;2022-06-03

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3